CAPR Stock — Capricor Therapeutics Inc.: Cash, EV, Pipeline

What they do

Capricor Therapeutics, Inc. is a biotechnology company focused on the development and potential commercialization of cell and exosome-based therapeutics for the treatment of Duchenne muscular dystrophy (“DMD”), a rare genetic disorder characterized by progressive muscle degeneration and premature death, as well as other diseases with significant unmet medical need.

Source: 10-K FY2025 via SEC EDGAR

Share price

$9.88

Market cap

$574.3M

Cash

$197.6M

Enterprise value

$376.7M

Balance sheet

Cash	$197.6M
Debt	$0.0M
Net cash	$197.6M
Enterprise value	$376.7M
Basic shares	58.1M shares
Fully diluted shares	75.1M shares
Fully diluted market cap	$741.9M
Cash per share	$3.40
Quarterly burn	$31.5M
Cash runway	7.6 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-10.

Share structure

Common

58.1M

Pre-funded warrants

0.0M

Options

13.6M

RSUs

0.0M

Warrants

3.3M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

75.1M

Cap table as of 2026-06-30.

Price history

Loading CAPR daily closes…

Loading price history…

Next catalyst

deramiocel · Nov 22, 2026 · guided in 11d

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDNov 22, 2026 in 11d	deramiocel BLA for Duchenne muscular dystrophy (PDUFA target action date)	Not disclosed	Duchenne muscular dystrophy (PDUFA target action date)	November 22, 2026

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Deramiocel

Phase 3 · Active Modality: cardiosphere-derived cell (CDC) product

Aliases CAP-1002

Partnerships Nippon Shinyaku: Japan Distribution Agreement (2023). U.S. Commercialization and Distribution Agreement (Jan 2022) — disputed, Capricor filed for preliminary injunction May 7, 2026; Europe term sheet expired Apr 1, 2026, not extended

Indications

Duchenne muscular dystrophy (DMD) (Phase 3)

Catalysts

— August 22, 2026

Status note BLA submitted late 2024, Priority Review, PDUFA Aug 31, 2025; CRL received Jul 2025. Type A meeting Aug 2025 aligned regulatory path on additional HOPE-3 Phase 3 data; CRL response submitted (FDA accepted, new PDUFA Aug 22, 2026). HOPE-3 published in The Lancet Jul 2026; Cellular, Tissue and Gene Therapies Advisory Committee voted 3-9 against substantial evidence of effectiveness for cardiomyopathy (Jul 29, 2026); BIMO inspection Jul 2026 (Form 483, one observation). Company plans BLA amendment with 24-month open-label extension data. Mesoblast patent infringement suit filed Jul 16, 2026.

StealthX exosome platform

Preclinical · Active Modality: exosome (extracellular vesicle) delivery platform

Aliases StealthX

Partnerships NIH, NIAID, Johns Hopkins University (research collaborations); Life Technologies/Thermo Fisher (cell line license, Mar 2022); CSMC (Exosomes License Agreement, May 2014)

Indications

Various diseases (therapeutic applications under exploration) (Stage not disclosed)

Status note Platform exploration for targeted RNA, protein and small molecule therapeutics; no clinical candidate stated in excerpts.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Deramiocel (CAP-1002)
Lead indication	Muscular Dystrophies; Muscular Dystrophy, Duchenne; Muscular Disorders, Atrophic
Lead phase	Phase 3
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05126758	Phase 3	Active, not recruiting	Sponsor	Capricor Inc.	—	Muscular Dystrophies; Muscular Dystrophy, Duchenne; Muscular Disorders, Atrophic	—
NCT04428476	Phase 2	Active, not recruiting	Sponsor	Capricor Inc.	—	Duchenne Muscular Dystrophy	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Capricor Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Tang Capital Partners	4,099,900	+700,000	4.48%	2026-08-14
RA Capital Management	1,507,844	no change	0.32%	2026-08-14
Boxer Capital	1,395,156	+805,156	2.53%	2026-08-14
Ikarian Capital	604,215	+76,200	2.38%	2026-08-14
RTW Investments	250,000	no change	0.05%	2026-08-14
ADAR1 Capital Management	90,593	no change	0.10%	2026-08-14
Ally Bridge Group	0	-113,899	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

CAPR — Capricor Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

CAPR — Capricor Therapeutics Inc.